Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until January 19, 2026 to file lead plaintiff applications in a securities class action lawsuit against Jayud Global Logistics Limited (“Jayud” or the “Company”) (NasdaqCM: JYD), if they purchased […]

(NYSE:FCX), SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) — Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Freeport-McMoRan Inc. (NYSE: FCX) publicly traded securities between February 15, 2022 and September 24, 2025, inclusive (the “Class Period”), have until Monday, January 12, 2026 to seek appointment as lead plaintiff of the Freeport-McMoRan

FCX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Freeport McMoRan Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit GlobeNewswire December 06, 2025 SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) — Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Freeport-McMoRan Inc. (NYSE: FCX) publicly

(HKSE:1877.HK),(Shenzhen:688180.SS), Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful improvement with toripalimab plus chemotherapy as 1st-line treatment for R/M NPC, achieving mOS of 64.8 months and a 5-year OS rate of 52.3%. Torpalimab plus chemotherapy has been approved in over 40 countries, representing the new standard of care for the 1st

Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients GlobeNewswire December 06, 2025 Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful improvement with toripalimab plus chemotherapy as 1st-line treatment for R/M NPC, achieving mOS of 64.8 months and a 5-year OS rate

SRN Advisors, LLC (SRN) announced today that the Siren DIVCON Dividend Defender ETF (CBOE: DFND), an index-based exchange-traded fund (“ETF”) managed by SRN, will reorganize into and with the Siren DIVCON Leaders Dividend ETF (CBOE: LEAD) (the “Funds”), also an index-based ETF managed by SRN. The reorganization was approved by the Board of Trustees (the

Bozen, Italy–(Newsfile Corp. – December 5, 2025) – Transfeero ends 2025 as one of the strongest years in its history, solidifying its position as a leading global provider of private transportation services. The platform designed to connect travelers seeking reliable and convenient mobility solutions with a worldwide network of professional drivers and licensed transport companies

Product:Sweet and Savory Mix Issue: Food – Microbial contamination – Salmonella Distribution:Ontario Online link SOURCE Canadian Food Inspection Agency (CFIA) https://rt.newswire.ca/rt.gif?NewsItemId=C3672&Transmission_Id=202512052104CANADANWWEB______C3672&DateId=20251205

PCs FOR PEOPLE announced today that Cofounder and CEO, Casey Sorensen, is departing from his role effective December 26, 2025. Sorensen, with the nonprofit since 2008, turned a simple idea of getting computers to low-income families into a self-sustaining model, where each region funds its own start-up costs. “Casey worked tirelessly to shape PCs for

Phase 2 results selected as one of only 10 featured presentations in the Poster Tour at the 2025 Parkinson Study Group (PSG) Annual Meeting Pivotal Phase 3 ARISE trial evaluating solengepras as an adjunctive treatment in Parkinson's disease is underway and actively enrolling patients BOSTON, Dec. 05, 2025 (GLOBE NEWSWIRE) — Cerevance, a clinical-stage biopharmaceutical